{"filings":[{"id":2144318,"accession_number":"0001213900-26-086939","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2026-08-10T11:15:14+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MoonLake Phase 3 IZAR-1 meets all endpoints; Q2 cash $537M, runway to mid-2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IZAR-1 Week 16: ACR50 42.1%, ACR20 66.5%, MDA 41.2%, PASI90 61% for sonelokimab 60mg.","Q2 2026 cash $537.0M; expects runway to mid-2028; up to $400M non-dilutive from Hercules.","Q2 R&D expenses $50.2M vs $54.5M in Q1; G&A $11.4M vs $15.5M in Q1.","IZAR-1 continues to Week 52; full readout H1 2027; IZAR-2 enrollment completion expected Q3 2026.","HS BLA submission expected end Sep 2026; PDUFA date allocation and Priority Review decision end Nov 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1645843,"accession_number":"0001213900-26-078031","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2026-07-14T21:31:54+00:00","items":["8.01"],"status":"ready","headline":"MoonLake Immunotherapeutics raises additional $30M from underwriters' overallotment exercise","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwriters exercised in full their option to purchase 1,500,000 additional ordinary shares.","Gross proceeds of $30.0 million from the sale of the option shares, before underwriting discounts.","Closing of the option share issuance occurred on July 14, 2026.","The option was part of a previously announced public offering of ordinary shares and pre-funded warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1258276,"accession_number":"0001213900-26-071721","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2026-06-25T10:18:36+00:00","items":["1.01","9.01"],"status":"ready","headline":"MoonLake Immunotherapeutics launches $200M public offering of 9M shares at $20.00 each","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering consists of 9,000,000 Class A ordinary shares at $20.00/share plus pre-funded warrants for up to 1,000,000 shares at $19.9999 each.","Underwriters granted 30-day option to purchase up to 1,500,000 additional shares at the offering price less discounts.","Gross proceeds expected to be $200 million before underwriting discounts and offering expenses.","Offering expected to close June 25, 2026; securities sold under effective shelf registration statement (File No. 333-274286).","Pre-funded warrants exercisable immediately at $0.0001/share, subject to beneficial ownership limitations (4.99% default)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1176798,"accession_number":"0001213900-26-070362","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2026-06-22T11:00:32+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"MoonLake Phase 3 VELA Week 52: 67% HiSCR75, 33% HiSCR100; BLA submission end-Sept 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Across VELA-1/2, 67.2% of SLK-treated patients achieved HiSCR75, 33.1% HiSCR100 at Week 52 (n=396).","26.0% achieved IHS4-100 remission; HiSQOL improved by mean -15.0 points from baseline.","46.5% of patients had marked pain reduction (≥3-point drop in worst skin pain NRS).","VELA-TEEN interim: ~68% HiSCR75, ~45% HiSCR100 at Week 24 in adolescents (n=22).","BLA submission for SLK in HS expected end of September 2026; PDUFA date by late Nov 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":946361,"accession_number":"0001213900-26-066821","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2026-06-09T20:30:15+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"MoonLake shareholders approve 5M share increase to equity plan at 2026 AGM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to 2022 Equity Incentive Plan, adding 5,000,000 Class A shares for awards.","Plan now includes one-year minimum vesting requirement, revised director compensation limits, and term through 2036.","Director Spike Loy re-elected with 92.4% of votes cast; auditor Baker Tilly ratified with 99.9% support.","Advisory vote on executive compensation passed with 98.6% of votes cast in favor.","Total shares authorized under the plan now 9,353,948, subject to adjustment provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":758916,"accession_number":"0001213900-26-063125","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2026-06-01T10:20:20+00:00","items":["1.01"],"status":"ready","headline":"MoonLake Immunotherapeutics signs commercial supply and capacity agreements with Vetter for sonelokimab","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Master Commercial Supply Agreement signed May 22, 2026 with Vetter for manufacturing pre-filled application systems.","Capacity Agreement commits MoonLake to binding annual minimum and maximum quantity orders; failure may trigger compensation.","Agreements include pricing adjustment provisions based on Vetter’s cost increases and change-of-control termination rights.","Sonelokimab is MoonLake’s key product candidate; deal supports potential commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95822,"accession_number":"0001821586-26-000005","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2026-05-11T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MoonLake aligns with FDA on BLA for sonelokimab in HS; Q1 cash $357.9M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA pre-BLA meeting positive; alignment on submission plans, adolescent data inclusion, and safety strategy.","BLA submission planned for end of Sep 2026; Priority Review decision expected within 60 days.","Proposed label includes ~43% HiSCR75 response and ~29pp delta-to-placebo from MIRA trial, highest in HS.","Cash $357.9M as of Mar 31, 2026; runway to end of 2027; up to $400M non-dilutive debt facility available.","R&D expenses $54.5M (stable); G&A $15.5M with $4.8M accelerated stock option cancellation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109150,"accession_number":"0001213900-26-018967","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["1.01","2.02","2.03","5.02","7.01","8.01","9.01"],"status":"ready","headline":"MoonLake reports positive Phase 2 axSpA data: 81% ASAS40 at Week 12; amends Hercules loan for up to $400M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 S-OLARIS trial: 81% of SLK-treated patients achieved ASAS40 response at Week 12 (n=26, mNRI).","Over 80% achieved clinically important improvement per ASDAS-CRP; PET/MRI showed reduced inflammation and osteoblast activity.","Cash, equivalents and short-term marketable debt securities: $394M as of Dec 31, 2025; runway into H2 2027.","Amended Hercules Capital debt facility; drew $25M; up to $400M in future non-dilutive funding available.","Director Simon Sturge to resign effective Feb 28, 2026; Dr. Jorge Santos da Silva appointed Interim Chair."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109149,"accession_number":"0001213900-26-002344","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MoonLake gets FDA clarity on SLK in HS; no new trials needed for BLA submission","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA confirms MoonLake can establish substantial evidence of effectiveness using existing VELA-1, VELA-2, and MIRA trials; no additional HS trials required.","BLA submission for Sonelokimab in HS on track for H2 2026; Investor Day set for Feb 23, 2026 to discuss FDA feedback and new data.","FDA advised including VELA-2 results in BLA to inform safety profile, regardless of role in establishing effectiveness.","Upcoming milestones: Phase 2 S-OLARIS (axSpA) Q1 2026; Phase 3 IZAR-1 (PsA) mid-2026; VELA-TEEN adolescent HS readout mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125646,"accession_number":"0001821586-25-000021","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MoonLake Q3 2025: $380.5M cash, positive Phase 2 PPP data for Sonelokimab","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $380.5M as of Sept 30, 2025; runway into H2 2027.","R&D expenses $60.6M (up from $49.8M) driven by trial ramp-up and BLA prep.","Phase 2 LEDA PPP: 64% mean PPPASI reduction, 39% PPPASI75 at week 16; no approved therapies.","VELA-TEEN interim: 46% HiSCR75 in adolescent HS at week 16 (n=11); BLA submission Q3/Q4 2026.","FDA Type B meeting Dec 15, 2025 to discuss SLK in HS evidence for BLA."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125645,"accession_number":"0001213900-25-106723","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"MoonLake Immunotherapeutics raises $75M in equity offering of 7.1M shares at $10.50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 7,142,857 Class A ordinary shares at $10.50 per share for gross proceeds of $75M.","Underwriting agreement with Leerink Partners LLC; expected close on November 6, 2025.","Shares offered under existing shelf registration statement on Form S-3 (File No. 333-274286)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142367,"accession_number":"0001213900-25-092614","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MoonLake VELA Ph3: VELA-1 meets primary HiSCR75 (p<0.001); VELA-2 misses but shows significance on treatment policy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VELA-1 achieved HiSCR75 at week 16 with 34.8% vs 17.5% placebo, delta 17.3% (p<0.001).","VELA-2 primary composite analysis p=0.053; pre-specified treatment policy gave 35.9% vs 25.6% (p=0.033).","Combined: HiSCR75 35.4% vs 21.6% (p<0.001); all secondary endpoints significant (pain, DLQI, HiSQOL).","Safety favorable: no suicidal ideation, MACE; oral candidiasis 7.3% on sonelokimab vs 0.4% placebo.","Next milestones: Q4 2025 LEDA (PPP), Q1 2026 S-OLARIS (axSpA), Q2 2026 VELA 52-week data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142366,"accession_number":"0001821586-25-000016","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MoonLake Q2 cash $425M; Phase 3 HS readout expected Sept 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["R&D expenses Q2 $49.8M (up from $36.5M Q1) on trial ramp-up and BLA preparation.","Cash & equivalents $425.1M; up to $500M non-dilutive debt facility from Hercules Capital.","Phase 3 VELA (HS) top-line readout on track for ~September 2025; BLA submission planned mid-2026.","Phase 2 LEDA (PPP) interim readout reported; primary readout expected Q4 2025.","Cash runway extended into 2028 to support sonelokimab launch in 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160400,"accession_number":"0001213900-25-052140","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MoonLake shareholders elect all director nominees and approve auditor and say-on-pay at AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All three Class III director nominees elected: Dr. Jorge Santos da Silva, Simon Sturge, Dr. Andrew Phillips with over 53M votes for each.","Ratification of Baker Tilly US, LLP as independent auditor approved: 59,310,209 for, 2,856 against, 8,438 abstentions.","Advisory vote on executive compensation passed with 53,464,199 for, 109,913 against, 8,983 abstentions, 5,738,408 broker non-votes.","Total shares entitled to vote: 63,474,253 Class A and 729,320 Class C ordinary shares as of record date April 10, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160399,"accession_number":"0001821586-25-000009","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MoonLake reports Q1 2025 cash of $480.1M, secures up to $500M debt facility; Phase 3 HS enrollment complete","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and short-term marketable debt securities of $480.1M as of March 31, 2025.","Up to $500M non-dilutive debt facility with Hercules Capital; $75M drawn at close, extends cash runway into 2028.","Phase 3 VELA program in hidradenitis suppurativa fully enrolled; top-line results expected around September 2025.","R&D expenses $36.5M (similar to prior quarter); G&A expenses $11.0M (up from $9.2M).","Interim readout of Phase 2 LEDA trial in palmoplantar pustulosis presented; primary endpoint readout expected 2H 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160398,"accession_number":"0001213900-25-036363","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"MoonLake to post investor presentation for Capital Markets Day; no specific figures disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["MoonLake Immunotherapeutics will post an investor presentation for its Capital Markets Day on April 29, 2025.","Presentation covers financial position, near-term clinical catalysts, and strategic outlook; no numbers in this filing.","Presentation and webcast replays will be available on MoonLake's IR website at https://ir.moonlaketx.com."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160397,"accession_number":"0001213900-25-028366","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"MoonLake secures up to $500M non-dilutive loan from Hercules Capital; $75M drawn at close","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Up to $500M non-dilutive term loan facility from Hercules Capital; $75M funded at close on March 31, 2025.","Additional tranches up to $125M upon VELA Phase 3 HS success; further tranches for PsA and BLA acceptance.","Facility matures April 1, 2030; interest rate prime+1.45% (floor 8.45%), 0.25% reduction on FDA BLA acceptance.","Company had $448M cash (from 10-K); combined facility expected to fund sonelokimab launch in 2027.","Capital Markets Update April 29, 2025: VELA baseline characteristics, primary endpoint readout timing, and Phase 2 LEDA interim data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178665,"accession_number":"0001821586-25-000004","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MoonLake reports FY 2024 net loss of $121.2M, cash of $448M; advances sonelokimab to Phase 3","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for 2024 was $121.2M, compared to $44.1M in 2023, driven by increased R&D spending.","R&D expenses rose to $112.8M in 2024 from $31.8M in 2023 as Phase 3 trials for HS and PsA started.","Cash and equivalents of $448.0M as of Dec 31, 2024, down from $493.9M in Q3 2024; runway to end of 2026.","Initiated Phase 3 VELA (HS), Phase 3 IZAR (PsA), plus Phase 2 trials in PPP, axSpA, and adolescent HS.","Capital Markets Update planned for Q2 2025 to discuss Phase 3 HS data and financials."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195332,"accession_number":"0001213900-24-110169","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2024-12-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"MoonLake director resigns; CEO, CSO, CFO each to receive $4M equity grants in Jan 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Kara Lassen resigns from Board effective Dec 31, 2024, due to new role at Roche Pharma; no dispute with Company.","Board approved long-term incentive program with annual equity grants; employees may elect restricted stock awards or stock options.","CEO Dr. Jorge Santos da Silva, CSO Dr. Kristian Reich, and CFO Matthias Bodenstedt each expected to receive $4M grant date fair value in Jan 2025, vesting over four years.","Board size reduced from 7 to 6 directors following resignation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195331,"accession_number":"0001821586-24-000028","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MoonLake Q3 cash $493.9M; Phase 3 HS readout on track for mid-2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, equivalents and short-term debt securities of $493.9M as of Sep 30; runway to end of 2026.","R&D expenses of $35.7M in Q3, up from $23.7M prior quarter, driven by Phase 3 HS ramp-up.","Phase 3 VELA program in HS actively enrolling; primary endpoint readout anticipated as of mid-2025.","Phase 3 PsA program (IZAR-1 and IZAR-2) enrollment expected to commence imminently.","Additional Phase 2 trials in PPP, axSpA, and Phase 3 adolescent HS to start around year-end 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211585,"accession_number":"0001213900-24-077513","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2024-09-11T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"MoonLake Immunotherapeutics posts investor presentation for Capital Markets Day on September 11, 2024","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Investor presentation covers financial position, near-term catalysts, and publication roadmap.","Presentation and webcast replay available on company's IR website at ir.moonlaketx.com.","No specific financial results or guidance disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211584,"accession_number":"0001821586-24-000024","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MoonLake reports $519.8M cash; initiates Phase 3 VELA in HS, positive FDA/EMA feedback for PsA Phase 3","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 cash, equivalents and short-term debt securities of $519.8M; cash runway to end-2026 unchanged.","R&D expenses $23.7M (up from $13.0M prior quarter) driven by new trial initiations; G&A $6.9M.","Phase 3 VELA program in hidradenitis suppurativa (HS) initiated; topline HiSCR75 primary endpoint expected mid-2025.","Positive FDA and EMA feedback on regulatory path for Phase 3 IZAR program in psoriatic arthritis; topline results expected end-2026.","Capital Markets Update on Sept 11; Phase 3 VELA TEEN in adolescent HS targeted for year-end 2024 initiation."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230285,"accession_number":"0001213900-24-051263","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA and EMA back MoonLake's Phase 3 program for sonelokimab in psoriatic arthritis","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA and EMA unanimously supported MoonLake's proposed Phase 3 IZAR program for sonelokimab in PsA.","Phase 3 design: ~1,500 patients across two trials (IZAR-1 bio-naïve, IZAR-2 TNF-IR with risankizumab reference).","Doses 60mg and 120mg; primary endpoint ACR50 at week 16; first patient Q4 2024, topline readout end-2026.","Follows positive FDA/EMA feedback for HS Phase 3 VELA program; Phase 3 HS recruitment already started.","Phase 2 ARGO data plus IZAR intended to support BLA and EU MAA for sonelokimab in PsA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230284,"accession_number":"0001213900-24-050194","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MoonLake Immunotherapeutics 2024 AGM: all director nominees elected, say-on-pay approved, annual frequency adopted","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Director nominees Catherine Moukheibir (50.4M for) and Dr. Ramnik Xavier (53.9M for) elected; 4.24M broker non-votes.","Baker Tilly ratified as independent auditor with 52.6M for vs 6.4M abstentions.","Advisory vote on executive compensation passed with 54.7M for (99.99% of votes cast).","Advisory vote on frequency: 54.2M chose 1 year; company will hold annual say-on-pay votes going forward."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230283,"accession_number":"0001821586-24-000019","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MoonLake Q1 cash $547.1M; positive FDA/EMA feedback for Phase 3 sonelokimab in HS","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and equivalents $547.1M at March 31, 2024, expected to fund operations to end of 2026.","R&D expense $13.0M in Q1 (up from $8.1M prior Q) due to trial initiations; G&A $6.8M.","Positive FDA and EMA feedback for Phase 3 VELA program in HS; topline data expected mid-2025.","ARGO Phase 2 in PsA: up to 52% ACR50+PASI100 and 61% MDA at week 24, suggesting best-in-class profile.","Plans to initiate four additional trials in PPP, juvenile HS, seronegative spondyloarthritis in 2H 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248696,"accession_number":"0001213900-24-021233","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2024-03-11T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"MoonLake reports 24-week PsA data with ~60% ACR50; plans Phase 3 HS trials in Q2 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ARGO trial: ~60% ACR50 at week 24; ~40% ACR70; >80% PASI90; ~60% PASI100; low discontinuation ~5%.","Composite responses: ACR50+PASI100 up to 52%, MDA up to 61%; sonelokimab outperformed adalimumab.","Regulatory feedback from FDA/EMA supports Phase 3 HS program (VELA) enrolling 800 patients; top-line data expected mid-2025.","US real-world data: 2M diagnosed HS patients; market opportunity >$10B by 2035; low biologic penetration ~3%.","Four additional clinical trials imminent in new indications (palmo-plantar pustulosis, juvenile HS, seronegative SpA)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248695,"accession_number":"0001821586-24-000007","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MoonLake FY 2023 net loss $44.1M; cash $511M; sonelokimab Phase 3 prep advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and short-term marketable debt securities $511.0M at Dec 31, 2023, up from $496M at Sep 30, 2023.","Net loss for FY 2023 $44.1M, improved from $64.5M in FY 2022.","R&D expenses $31.8M in FY 2023, down from $42.0M in FY 2022.","Completed positive Phase 2 data for sonelokimab in HS and PsA; FDA/EMA feedback supports Phase 3 VELA program in HS.","Raised $85M gross proceeds from at-the-market offerings; cash runway expected to end of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248694,"accession_number":"0001213900-24-016737","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2024-02-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MoonLake gets FDA & EMA support for Phase 3 sonelokimab in hidradenitis suppurativa","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA and EMA both support Phase 3 design for sonelokimab (SLK) in HS; trial named VELA.","Phase 3 will enroll 800 patients; single 120mg dose vs placebo over 16 weeks; primary endpoint HiSCR75.","First patient randomization expected Q2 2024; primary endpoint readout mid-2025.","Combined Phase 2 and Phase 3 data to support BLA and EU marketing application.","End-of-Phase 2 meeting for PsA with FDA expected Q2 2024; Phase 3 start Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266190,"accession_number":"0001821586-23-000020","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MoonLake Q3 cash $496M; positive Phase 2 data for sonelokimab in HS and PsA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash & equivalents $496.0M at Sept 30, 2023, expected to fund Phase 3 programs and regulatory filings.","Positive full 24-week data from Phase 2 MIRA trial in hidradenitis suppurativa announced.","Landmark 12-week data from Phase 2 ARGO trial in psoriatic arthritis presented.","R&D expenses $7.6M in Q3 (down from $8.7M Q2); G&A expenses $5.4M (up from $4.5M).","Phase 3 initiation targeted for 2024; End of Phase 2 FDA meeting in December 2023; 24-week ARGO data expected Q1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266189,"accession_number":"0001628280-23-036888","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"MoonLake Phase 2 ARGO trial meets primary endpoint; sonelokimab ACR50 46-47% vs placebo","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ACR50 achieved by 46% (60mg) and 47% (120mg) with induction at week 12 (p<0.01 vs placebo; ITT-NRI).","Key secondary endpoint PASI90 reached by 77% (60mg) and PASI100 by 58% (60mg) at week 12.","Discontinuation rate <4%; no new safety signals; oral candidiasis <2%, no IBD/MACE/SI/B.","Sonelokimab numerically outperformed adalimumab on primary and key secondary endpoints.","Company plans Phase 3 in PsA; end-of-Phase 2 regulatory meeting timing to be announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266188,"accession_number":"0001013762-23-003933","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2023-10-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MoonLake announces positive 24-week Phase 2 MIRA results; 57% HiSCR75, 120mg dose confirmed for Phase 3","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["57% of patients on sonelokimab 120mg achieved HiSCR75 at week 24 (+10 ppt from week 12); 38% achieved HiSCR90 (+14 ppt).","Complete inflammatory remission (IHS4-100) in 24% of patients; 31% AN 100 and 49% DT 100 at week 24 with 120mg.","120mg Q4W maintenance dose confirmed as optimal based on efficacy, safety, and pharmacokinetics; safety consistent with IL-17 class.","Adalimumab non-responders switching to sonelokimab at week 12 achieved HiSCR75 rates similar to patients randomized to sonelokimab at baseline.","Company on track to discuss Phase 3 development plans with FDA by end of 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283434,"accession_number":"0001213900-23-075653","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2023-09-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MoonLake holds Capital Markets Day; posts investor presentation on website","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation posted September 11, 2023; covers financial position, near-term catalysts, and publication roadmap.","No specific financial figures or guidance changes disclosed in the filing.","Event is a routine investor update; no material news beyond the presentation content."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283433,"accession_number":"0001213900-23-073296","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2023-09-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"MoonLake raises CEO, CSO, CFO salaries and bonuses citing MIRA trial success","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New annual base salaries July 1, 2023: CEO Jorge Santos da Silva CHF 600k (was CHF 450k), CSO Kristian Reich CHF 600k (was CHF 450k), CFO Matthias Bodenstedt CHF 475k (was CHF 325k).","Target bonuses raised to 55% of salary for CEO and CSO, 50% for CFO (previously 50%, 50%, 40% respectively).","Board cites positive Phase 2 MIRA trial results and peer benchmarking as rationale for adjustments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283432,"accession_number":"0001213900-23-065274","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MoonLake reports Q2 cash $501.8M after $460M offering; positive Phase 2 MIRA data in HS","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised ~$460M gross in upsized public offering (8M shares at $50); cash & equivalents $501.8M at June 30, 2023.","Positive Phase 2 MIRA trial met primary endpoint HiSCR75 at week 12; sonelokimab showed highest clinical activity among tested therapies.","Completed randomization of 200 patients in Phase 2 ARGO PsA trial ahead of schedule; top-line 12-week data expected H1 Nov 2023.","R&D expenses $8.7M, G&A $4.5M for Q2 2023; no revenue (clinical-stage biotech).","Upcoming catalysts: MIRA 24-week data mid-Oct, ARGO 12-week data Nov, End of Phase 2 FDA meeting Dec 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302904,"accession_number":"0001628280-23-023905","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2023-06-29T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"MoonLake raises $460M in offering; Phase 2 MIRA trial meets primary endpoint with HiSCR75 at week 12","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 9.2M Class A ordinary shares at $50/sh (8M firm + 1.2M option) for $460M gross proceeds.","Phase 2 MIRA trial (234 patients) met HiSCR75 primary endpoint: 120mg dose had 29 ppt delta to placebo (p=0.0002).","HiSCR50 delta 38 ppt (p<0.0001); secondary endpoints including HiSCR90, IHS4, pain, quality of life all significant.","SLK safety consistent with prior IL-17 inhibitor profile; no new signals observed.","Entered global royalty-bearing license with RCT for Pichia pastoris manufacturing process for SLK."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302903,"accession_number":"0001628280-23-023381","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2023-06-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MoonLake's sonelokimab hits HiSCR75 with 29 ppt delta (p=0.0002) in Phase 2 HS trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint HiSCR75 met with 29 ppt delta vs placebo (p=0.0002) at week 12.","HiSCR50 achieved 38 ppt delta (p<0.0001), highest delta observed for any molecule in HS.","Secondary endpoints including HiSCR90, IHS4, and patient-reported pain/quality of life met statistical significance.","Safety profile consistent with known IL-17 inhibitor class; no new safety signals observed.","Dose of 120mg performed similarly to 240mg; 120mg considered optimal for further development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302902,"accession_number":"0001213900-23-047184","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2023-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MoonLake Immunotherapeutics announces 2023 AGM results; directors elected, auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Dr. Kara Lassen elected as Class I director with 37,996,564 votes for, 93,222 withheld.","Spike Loy elected as Class I director with 37,728,807 votes for, 360,979 withheld.","Ratification of Baker Tilly US, LLP as independent auditor passed with 41,585,151 votes for, 366 against.","Broker non-votes totaled 3,496,781 on director elections; none on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302901,"accession_number":"0001213900-23-041556","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2023-05-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"MoonLake Immunotherapeutics amends equity plans to provide automatic vesting upon change of control","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective May 15, 2023, Board amended Employee Share Participation Plan and Stock Option Plan to include single-trigger vesting upon Change of Control.","Amendments apply to all outstanding and future equity awards, including those to named executive officers.","Awards will vest in full automatically upon a Change of Control as defined in the Plans.","Change aligns compensation arrangements with market practice per the Company's review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302900,"accession_number":"0001213900-23-030849","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2023-04-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MoonLake Immunotherapeutics posts Capital Markets Day presentation; no financial results disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation covers financial position, near-term catalysts, and publication roadmap.","Presentation available on company IR website; webcast replay will be posted.","No specific financial data or updated guidance included in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322539,"accession_number":"0001821586-23-000004","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2023-03-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Moonlake reports FY2022 net loss $64.5M; HS trial top-line expected June 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for year ended Dec 31, 2022 was $64.5M vs $53.6M for prior period (March 2021 to Dec 2021).","Cash, equivalents and short-term marketable debt securities $72.1M at Dec 31, 2022; runway into 2H 2024.","Phase 2 HS trial top-line results expected around end of June 2023; final readout by Q4 2023.","Phase 2 PsA trial enrollment on schedule; top-line results anticipated at end of 2023.","Capital Markets Day set for April 19, 2023 in New York and via webcast."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322538,"accession_number":"0001213900-23-019254","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"MoonLake Immunotherapeutics confirms no deposits or securities at SVB","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Company aware of California regulator taking possession of Silicon Valley Bank.","Company states it holds no cash deposits or securities with SVB.","No financial exposure or impact from SVB collapse."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376471,"accession_number":"0001213900-22-033592","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2022-06-17T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"MoonLake Immunotherapeutics dismisses Withum and engages Baker Tilly as auditor post-merger","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee dismissed WithumSmith+Brown as independent auditor effective June 15, 2022.","Baker Tilly US, LLP was engaged as the new independent registered public accounting firm on the same date.","Withum's prior reports contained a going-concern paragraph related to the SPAC's pre-merger status; no disagreements or reportable events occurred.","The business combination with MoonLake AG closed on April 5, 2022, resolving the going-concern uncertainty."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376470,"accession_number":"0001213900-22-031476","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2022-06-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MoonLake posts Capital Markets Day presentation; no specific data disclosed in filing text","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company filed a Form 8-K announcing the posting of an investor presentation for Capital Markets Day on June 7, 2022.","Presentation covers clinical development program and recent developments, but no concrete figures or updates are provided in the excerpt.","Full presentation is available on the company's IR website; no financial or pipeline details are included in the 8-K text.","This filing is procedural under Regulation FD; material content requires review of the actual presentation slides."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376468,"accession_number":"0001213900-22-027102","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K/A","filed_at":"2022-05-16T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"MoonLake AG reports Q1 2022 net loss of $15.9M; business combination with Helix closes raising $134.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $15.88M for three months ended March 31, 2022; accumulated deficit of $69.5M.","Cash of $8.8M; current liabilities exceeded current assets by $25.3M as of March 31, 2022.","Short-term loans of $30M from BVF and Cormorant repaid after Business Combination closed April 5, 2022.","Business Combination with Helix closed on April 5, 2022, raising $134.7M net of expenses.","Company is a clinical-stage biopharma focused on Nanobody sonelokimab (SLK) for inflammatory diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376469,"accession_number":"0001213900-22-019217","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2022-04-11T23:59:59+00:00","items":["1.01","2.01","9.01","3.02","3.03","5.01","5.02","5.03","5.05","5.06","7.01"],"status":"ready","headline":"MoonLake Immunotherapeutics (fka Helix Acquisition) closes business combination, lists on Nasdaq","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Closed business combination Apr 5, 2022; Helix acquired MoonLake AG, renamed MoonLake Immunotherapeutics (MLTX).","Issued 36.9M Class A shares and 15.8M Class C shares; PIPE investors subscribed 11.7M Class A shares at $10.00 each, grossing ~$116M.","Existing MoonLake AG shareholders received 18.5M Class A and 15.8M Class C shares; lock-up periods of 6 to 12 months apply.","Helix contributed $134.6M to MoonLake AG, including $15M loan repayment to Cormorant Asset Management.","New equity incentive plan adopted; initial grants of 45,000 options per non-management director; indemnification agreements executed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394810,"accession_number":"0001213900-22-016984","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2022-03-31T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Helix Acquisition shareholders approve business combination with MoonLake, name change to MoonLake Immunotherapeutics","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Business Combination Agreement with MoonLake Immunotherapeutics AG approved; 11.5M votes for, 549K against.","Name change to \"MoonLake Immunotherapeutics\" and adoption of amended charter authorized.","Shareholders redeemed 8,080,845 Class A shares at ~$10.00/share for aggregate ~$80.8M cash.","Incentive Plan (MoonLake Immunotherapeutics 2022 Equity Incentive Plan) approved with 12.0M votes for.","Issuance of shares to BVF shareholders and ML Parties approved under Nasdaq listing rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394809,"accession_number":"0001213900-22-014894","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2022-03-24T23:59:59+00:00","items":["2.03","9.01"],"status":"ready","headline":"Helix Acquisition Corp. receives $150,000 working capital loan from affiliate Cormorant Asset Management","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Cormorant Asset Management LP, an affiliate of Helix officers, loaned $150,000 for working capital.","Loan is non-interest bearing, non-convertible, payable upon consummation of a business combination.","If no business combination occurs, the loan is forgiven except for funds available outside trust account.","Helix is pursuing a business combination with MoonLake Immunotherapeutics AG as previously disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394808,"accession_number":"0001213900-22-009481","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2022-02-25T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Helix enters $15M convertible loan with MoonLake; rollover option into PIPE","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Cormorant Private Healthcare Fund IV lends MoonLake $15M interest-free, unsecured, for general corporate purposes pending business combination.","Loan matures 2 days after deal closing or June 30, 2022; may roll over into Cormorant's $27.5M PIPE commitment.","If deal terminates, loan converts into MoonLake shares; subordinated to all creditors but senior to existing subordinated loans.","Proceeds cannot be used to repay existing $15M loan from Biotechnology Value Funds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":413469,"accession_number":"0001213900-21-063323","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2021-12-03T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"Helix Acquisition to restate financials after reclassifying all public shares as temporary equity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Non-reliance on previously issued financial statements from Oct 2020 through Sep 2021 due to share classification error.","Re-evaluation prompted by SEC comment letter; all public shares now classified as temporary equity.","Restatements to be filed as amendments to Form 10-Q for Q3 2021 and Form 10-K for 2020.","Material weakness in internal control over financial reporting identified; remediation plan to be detailed.","No impact on cash position or trust account established in connection with the IPO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":413468,"accession_number":"0001213900-21-051257","cik":1821586,"company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","form_type":"8-K","filed_at":"2021-10-04T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Helix Acquisition Corp. announces business combination with MoonLake Immunotherapeutics; $115M PIPE","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Helix (HLXA) to combine with MoonLake Immunotherapeutics AG, a Swiss immuno-dermatology biotech.","PIPE of $115M at $10.00/share from investors including sponsor affiliate and existing MoonLake holders.","Combined company to rename as MoonLake Immunotherapeutics; Helix Class B shares convert to Class A 1:1.","Closing expected late Q4 2021/early Q1 2022, subject to shareholder approvals and minimum $150M cash condition.","Post-closing board: 7 directors (4 designated by MoonLake, 2 by Helix, plus Jorge Santos da Silva)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1373663394.4073873,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-10-04T23:59:59+00:00|413468"}